CORRESP Filing
Lexeo Therapeutics, Inc.
Date: Nov. 25, 2025 · CIK: 0001907108 · Accession: 0001193125-25-297231
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291269
Letter
Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-291269 Acceleration Request Requested Date: November 26, 2025 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “ Company ”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-291269) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736.
Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, New York 10010 November 25, 2025 VIA EDGAR U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720
Sincerely,
LEXEO THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, New York 10010 November 25, 2025 VIA EDGAR U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Re: Lexeo Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-291269 Acceleration Request Requested Date: November 26, 2025 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “ Company ”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-291269) (the “ Registration Statement ”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan J. Baier at (212) 497-7736. Sincerely, LEXEO THERAPEUTICS, INC. /s/ Jenny R. Robertson Jenny R. Robertson Chief Legal Officer cc: R. Nolan Townsend Lexeo Therapeutics, Inc. Megan J. Baier David G. Sharon Wilson Sonsini Goodrich & Rosati, P.C.